Art. -Nr.: HY-108471

CU-CPT22

12 Cited Publications

Kundenbewertung

Based on 12 publication(s) in Google Scholar

CU-CPT22 is a potent protein complex of toll-like receptor 1 and 2 (TLR1/2) inhibitor, and competes with the synthetic triacylated lipoprotein (Pam₃CSK₄) binding to TLR1/2 with a K_i of 0.41 µM. CU-CPT22 blocks Pam₃CSK₄-induced TLR1/2 activation with an IC₅₀ of 0.58 µM.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.08%
CAS. Nr.: 1416324-85-0
Formel: C₁₉H₂₂O₇
Molecular Weight:362.37

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

CU-CPT22 Chemical Structure

CAS. Nr.: 1416324-85-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
Chemical Information
Publications (12)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

TLR1

TLR2

Alle Toll-like Receptor (TLR) Isoform-spezifische Produkte anzeigen :

In Vitro

CU-CPT22 is a toll-like receptor 1 and 2 (TLR1/2) inhibitor with an IC₅₀ of 0.58±0.09 μM. It is demonstrated that CU-CPT22 is able to compete with Pam₃CSK₄ for binding to TLR1/2 with an inhibition constant (K_i) of 0.41±0.07 μM, which is consistent with its potency observed in the whole cell assay. Increasing the concentration of CU-CPT22 to 6 μM decreases the anisotropy to background levels. It is found that CU-CPT22 inhibits TLR1/2 signaling without affecting other TLRs, showing it is highly selective in intact cells. CU-CPT22 is found to have no significant cytotoxicity at various concentrations up to 100 μM in RAW 264.7 cells.? The result demonstrates that CU-CPT22 can inhibit about 60% of TNF-αand 95% of IL-1β at 8 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 1416324-85-0
Appearance Solid
Molecular Weight 362.37
Formel C₁₉H₂₂O₇
Color Yellow to orange
SMILES

O=C(C(C=C1O)=CC2=CC(OC)=C(O)C(O)=C2C1=O)OCCCCCC
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (12)

All WBELISAHistological Imaging/StainingIF

Sort by:

Journal Impact Factor

Theranostics

Ligand-directed oral lipidic nanoplatform enables sustained ferroptosis and immune reprogramming via multivalent transporter-mediated metronomic delivery. [Abstract]

2026 Jan 1;16(6):2952-2983. PMID: 41510171
Biomaterials

Cholesterol-modified DP7 enhances the effect of individualized cancer immunotherapy based on neoantigens. [Abstract]

2020 May;241:119852. PMID: 32120313

CU-CPT22 purchased from MedChemExpress. Usage Cited in: Biomaterials. 2020 May;241:119852. [Abstract]

The TLR2-MyD88-IKK-IκB-NF-κB signaling pathway was activated in DP7-C-stimulated BMDCs. Furthermore, Western blot results also showed that DP7-C failed to effectively activate MyD88 following treatment with TLR2 inhibitors (C29, CU-CPT22; 8 μM, 2 h), whereas DP7-C still activated MyD88 after treatment with the TLR4 inhibitor TAK242.
Cell Death Discov

Secretory LGALS3BP exacerbates sepsis-associated liver dysfunction by activating inflammasome-mediated pyroptosis. [Abstract]

2026 Jun 23. PMID: 42336831
Int J Biol Macromol

Mechanistic insights into the hepatic metabolism of lentinan: A TLR2-ROS-lysosome axis. [Abstract]

2026 Feb:347:150597. PMID: 41643971
Life Sci

Oscillating flow promotes inflammation through the TLR2-TAK1-IKK2 signalling pathway in human umbilical vein endothelial cell (HUVECs). [Abstract]

2019 May 1:224:212-221. PMID: 30914314

CU-CPT22 purchased from MedChemExpress. Usage Cited in: Life Sci. 2019 May 1:224:212-221. [Abstract]

WB for detecting the effect of CU-CPT22 (CU CPT, 0.58 μM; 1 h), an inhibitor of TLR2.
Sci Rep

Dysfunctional TLR1 reduces the therapeutic efficacy of chemotherapy by attenuating HMGB1-mediated antitumor immunity in locally advanced colorectal cancer. [Abstract]

2023 Nov 9;13(1):19440. PMID: 37945630
Curr Pharm Des

Interaction of Ectodomain of Respiratory Syncytial Virus G Protein with TLR2/ TLR6 Heterodimer: An In vitro and In silico Approach to Decipher the Role of RSV G Protein in Pro-inflammatory Response against the Virus. [Abstract]

2021;27(44):4464-4476. PMID: 34279194
Oral Dis

2020;00:1-13.

CU-CPT22 purchased from MedChemExpress. Usage Cited in: Oral Dis. 2020;00:1-13.

Representative H&E and F4/80 staining images of saline-injection, CFA-injection and CFA + CU-CPT22 (10 mg/kg; i.p.; administered once prior to TMJOA induction, and twice weekly thereafter) groups' synovium. In CFA-injection mice, the thickness of intimal layer at 2nd (b) and 4th (e) week was markedly higher than that in saline-injection mice (a, d); The intima layer thinned gradually in CTA + CU-CPT22 treated mice (c, f). Analogously, administration of CU-CPT22 (i) significantly inhibited the elevation of F4/80 positive staining in CFA-injection mice (h), compared with that of saline-injection mice (g), which displayed weak expression of F4/80 (Figure j stands for control with negative primary IgG).

CU-CPT22 purchased from MedChemExpress. Usage Cited in: Oral Dis. 2020;00:1-13.

The expression of anabolic factors aggrecan (ACAN) and type II collagen (Col2A1) at the 4th week was detected by immunofluorescence. In comparison with CFA-injection mice, CFA + CU-CPT22 (10 mg/kg; i.p.; administered once prior to TMJOA induction, and twice weekly thereafter) treated mice exhibited stronger and homogeneous positive expression of ACAN and Col2A1 on the condylar cartilage.

CU-CPT22 purchased from MedChemExpress. Usage Cited in: Oral Dis. 2020;00:1-13.

Immunoblots detection disclosed that pretreatment of CU-CPT22 (10 μM; pretreated 3 h) significantly reduced the production of TLR2, NF-κB p65, as well as catabolic factors (MMP3, MMP13) and inflammatory factors (TNF-α, COX-2) in chondrocytes induced by IL-1β (10 ng/mL).
Cell Tissue Res

Pyruvate kinase M2 activation protects against the proliferation and migration of pulmonary artery smooth muscle cells. [Abstract]

2020 Dec;382(3):585-598. PMID: 32719938
Anim Reprod Sci

The roles of Braun Lipoprotein in inducing tolerance of bovine endometrium infected by Escherichia coli. [Abstract]

2024 Jul:266:107513. PMID: 38843662

CU-CPT22 purchased from MedChemExpress. Usage Cited in: Anim Reprod Sci. 2024 Jul:266:107513. [Abstract]

Effect of TLR2 on the release of inflammatory mediators in EECs infected with LPS and E. coli in the presence of BLP. EECs were pretreated with the TLR2 inhibitor, CU-CPT22 (10 µM), before treatment for 4 h. EECs were treated with LPS (1 μg/mL) and BLP (1 μg/mL) in combination, or untreated (A-C). EECs were infected with JE5505 (1 × 10⁶ CFU) in combination with BLP (1 μg/mL) or left uninfected (D-F). Release of IL-6, IL-8, and IL-10 into the supernatant of EECs cultures was analyzed by ELISA, 12 h after treatment.
Biochem Cell Biol

SARS-CoV-2 E protein-induced THP-1 pyroptosis is reversed by Ruscogenin. [Abstract]

2023 Aug 1;101(4):303-312. PMID: 36927169
Oxid Med Cell Longev

Triptolide Inhibits Preformed Fibril-Induced Microglial Activation by Targeting the MicroRNA155-5p/SHIP1 Pathway. [Abstract]

2019 Apr 28:2019:6527638. PMID: 31182996

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 125 mg/mL (344.95 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7596 mL

13.7981 mL

27.5961 mL

5 mM

0.5519 mL

2.7596 mL

5.5192 mL

10 mM

0.2760 mL

1.3798 mL

2.7596 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (6.90 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: 2.5 mg/mL (6.90 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Kinase Assay^[1]

RAW 264.7 cells are planted in 6-well plates at 1,000,000 cells per well with 3 mL of medium and grown for 24 h at 37°C in a 5% CO₂ humidified incubator. After 24 h, non-adherent cells and media are removed and replaced with fresh RPMI 1640 medium (3 mL/well). Two wells of adherent macrophages are treated with Pam₃CSK₄ (300 ng/mL) as the positive control, two wells are treated with 8 μM CU-CPT22, and the other two wells are treated with 8 μM compound DMSO. Plates are then incubated for an additional 24 h. The medium is removed, the cells are washed with PBS (3×1 mL), the plate is put on ice, then 500 μL of lysis buffer is added to each well. The production of the cytokine interleukin-1β (IL-1β) and TNF-α is quantified with enzyme-linked immunosorbent assays (ELISA). The cytokine level in each sample is determined in duplicate^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
SDS (622 KB)
- English - EN (622 KB)
- Français - FR (622 KB)
- Deutsch - DE (622 KB)
- Norwegian - NO (622 KB)
- Español - ES (622 KB)
- Swedish - SV (622 KB)
- Italian - IT (622 KB)
- Korean - KR (622 KB)
- Portuguese - PT (622 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Cheng K, et al. Discovery of small-molecule inhibitors of the TLR1/TLR2 complex. Angew Chem Int Ed Engl. 2012 Dec 3;51(49):12246-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7596 mL	13.7981 mL	27.5961 mL	68.9903 mL
	5 mM	0.5519 mL	2.7596 mL	5.5192 mL	13.7981 mL
	10 mM	0.2760 mL	1.3798 mL	2.7596 mL	6.8990 mL
	15 mM	0.1840 mL	0.9199 mL	1.8397 mL	4.5994 mL
	20 mM	0.1380 mL	0.6899 mL	1.3798 mL	3.4495 mL
	25 mM	0.1104 mL	0.5519 mL	1.1038 mL	2.7596 mL
	30 mM	0.0920 mL	0.4599 mL	0.9199 mL	2.2997 mL
	40 mM	0.0690 mL	0.3450 mL	0.6899 mL	1.7248 mL
	50 mM	0.0552 mL	0.2760 mL	0.5519 mL	1.3798 mL
	60 mM	0.0460 mL	0.2300 mL	0.4599 mL	1.1498 mL
	80 mM	0.0345 mL	0.1725 mL	0.3450 mL	0.8624 mL
	100 mM	0.0276 mL	0.1380 mL	0.2760 mL	0.6899 mL

Keywords

CU-CPT22

12 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

CU-CPT22

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Pyroptosis Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Pattern Recognition Receptors Library

Immunology/Inflammation Compound Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Publications Citing Use of MedChemExpress (MCE) CU-CPT22

Alle Toll-like Receptor (TLR) Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (12)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

CU-CPT22

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Pyroptosis Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Pattern Recognition Receptors Library

Immunology/Inflammation Compound Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Publications Citing Use of MedChemExpress (MCE) CU-CPT22

Alle Toll-like Receptor (TLR) Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (12)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

CU-CPT22 Related Classifications

HY-108471 Related Classifications